Latest Insider Transactions at Apellis Pharmaceuticals, Inc. (APLS)
This section provides a real-time view of insider transactions for Apellis Pharmaceuticals, Inc. (APLS). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Apellis Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Apellis Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 03
2022
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+10.44%
|
$75,000
$15.09 P/Share
|
|
Aug 03
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-11.65%
|
$280,000
$56.43 P/Share
|
|
Aug 01
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.28%
|
$137,500
$55.99 P/Share
|
|
Jul 27
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
5,000
-14.6%
|
$285,000
$57.0 P/Share
|
|
Jul 27
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.74%
|
$75,000
$15.52 P/Share
|
|
Jul 21
2022
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
9,606
+8.71%
|
$134,484
$14.0 P/Share
|
|
Jul 19
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
5,000
-14.6%
|
$280,000
$56.42 P/Share
|
|
Jul 19
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+12.74%
|
$75,000
$15.52 P/Share
|
|
Jul 15
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.47%
|
$57,500
$46.33 P/Share
|
|
Jul 15
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.47%
|
$2,500
$2.67 P/Share
|
|
Jul 11
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
5,000
-10.44%
|
$240,000
$48.42 P/Share
|
|
Jul 11
2022
|
Adam J. Townsend Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
5,000
+9.45%
|
$75,000
$15.09 P/Share
|
|
Jul 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.26%
|
$564,000
$47.95 P/Share
|
|
Jul 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+0.97%
|
$37,000
$2.67 P/Share
|
|
Jun 27
2022
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
1,341
-50.0%
|
$61,686
$46.79 P/Share
|
|
Jun 23
2022
|
A. Sinclair Dunlop Director |
SELL
Open market or private sale
|
Indirect |
15,000
-4.99%
|
$675,000
$45.0 P/Share
|
|
Jun 22
2022
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
10,000
-7.96%
|
$440,000
$44.51 P/Share
|
|
Jun 17
2022
|
Victoria L. Brown Program Team Lead |
SELL
Open market or private sale
|
Direct |
2,698
-9.75%
|
$121,410
$45.0 P/Share
|
|
Jun 17
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
33,005
+3.42%
|
$66,010
$2.67 P/Share
|
|
Jun 16
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
10,000
-25.48%
|
$410,000
$41.78 P/Share
|
|
Jun 16
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,000
+20.3%
|
$130,000
$13.85 P/Share
|
|
Jun 15
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.47%
|
$48,750
$39.29 P/Share
|
|
Jun 15
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.47%
|
$2,500
$2.67 P/Share
|
|
Jun 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,500
+1.01%
|
$37,000
$2.67 P/Share
|
|
Jun 08
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
12,000
-1.33%
|
$528,000
$44.09 P/Share
|
|
Jun 01
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.23%
|
$102,500
$41.78 P/Share
|
|
May 27
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
10,000
-19.86%
|
$430,000
$43.0 P/Share
|
|
May 16
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.47%
|
$48,750
$39.18 P/Share
|
|
May 16
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.47%
|
$2,500
$2.67 P/Share
|
|
May 02
2022
|
Federico Grossi Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,500
-2.18%
|
$107,500
$43.56 P/Share
|
|
Apr 29
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
4,000
-0.45%
|
$176,000
$44.43 P/Share
|
|
Apr 29
2022
|
Pascal Deschatelets Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,000
+0.44%
|
$8,000
$2.67 P/Share
|
|
Apr 25
2022
|
Timothy Eugene Sullivan Chief Financial Officer |
SELL
Other acquisition or disposition
|
Direct |
3,750
-3.63%
|
-
|
|
Apr 25
2022
|
Nur Nicholson Chief Technical Officer |
SELL
Other acquisition or disposition
|
Direct |
1,875
-5.27%
|
-
|
|
Apr 25
2022
|
Karen Lewis Chief People Officer |
SELL
Other acquisition or disposition
|
Direct |
1,250
-5.33%
|
-
|
|
Apr 25
2022
|
Jeffrey Eisele Chief Development Officer |
SELL
Other acquisition or disposition
|
Direct |
1,250
-3.79%
|
-
|
|
Apr 25
2022
|
Cedric Francois Chief Executive Officer |
SELL
Other acquisition or disposition
|
Direct |
12,500
-1.31%
|
-
|
|
Apr 25
2022
|
David O. Watson General Counsel |
SELL
Open market or private sale
|
Direct |
5,000
-3.83%
|
$250,000
$50.0 P/Share
|
|
Apr 22
2022
|
A. Sinclair Dunlop Director |
BUY
Exercise of conversion of derivative security
|
Direct |
20,000
+18.0%
|
$280,000
$14.0 P/Share
|
|
Apr 21
2022
|
Adam J. Townsend Chief Commercial Officer |
SELL
Other acquisition or disposition
|
Direct |
1,875
-4.26%
|
-
|
|
Apr 21
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Other acquisition or disposition
|
Direct |
1,875
-3.59%
|
-
|
|
Apr 21
2022
|
Federico Grossi Chief Medical Officer |
SELL
Other acquisition or disposition
|
Direct |
1,875
-1.61%
|
-
|
|
Apr 21
2022
|
Pascal Deschatelets Chief Scientific Officer |
SELL
Other acquisition or disposition
|
Direct |
1,875
-0.21%
|
-
|
|
Apr 21
2022
|
David O. Watson General Counsel |
SELL
Other acquisition or disposition
|
Direct |
1,875
-1.42%
|
-
|
|
Apr 20
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
SELL
Open market or private sale
|
Direct |
7,000
-19.73%
|
$364,000
$52.53 P/Share
|
|
Apr 20
2022
|
Mark Jeffrey De Long Chief Business & Strat Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
7,000
+16.48%
|
$105,000
$15.52 P/Share
|
|
Apr 14
2022
|
Alec Machiels Director |
SELL
Open market or private sale
|
Direct |
1,250
-0.47%
|
$62,500
$50.9 P/Share
|
|
Apr 14
2022
|
Alec Machiels Director |
BUY
Exercise of conversion of derivative security
|
Direct |
1,250
+0.47%
|
$2,500
$2.67 P/Share
|
|
Apr 05
2022
|
Lukas Scheibler Chief Research Officer |
SELL
Open market or private sale
|
Direct |
609
-1.15%
|
$36,540
$60.09 P/Share
|
|
Apr 05
2022
|
Lukas Scheibler Chief Research Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
609
+1.14%
|
$7,917
$13.85 P/Share
|